search
Back to results

Evaluating Clinical Acceptance of a NPWT Wound Care System

Primary Purpose

Diabetic Foot Ulcer, Pressure Injury, Pressure Ulcer

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Invia Motion Endure
Sponsored by
Medela AG
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Foot Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adult subjects ≥18 years of age.
  • Signed, informed consent by patient or LAR within 72 hours of admission to burn center.
  • Patient is determined to be in need of NPWT for treatment of a diabetic foot ulcer, pressure injuries/pressure ulcer.
  • Patient is comfortable (e.g. not in pain)
  • Patient is willing and able to adhere to treatment protocol.

Exclusion Criteria:

  • Patient not willing to comply with f/u clinic visits.
  • Subjects with

    • Necrotic tissue with eschar present
    • Untreated osteomyelitis
    • Non-enteric and unexplored fistulas
    • Malignancy in wound
    • Exposed vasculature
    • Exposed nerves
    • Exposed anastomotic site of blood vessels or bypasses
    • Exposed organs
  • Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.
  • Patients with concurrent conditions or co-morbidities that in the opinion of the investigator may compromise patient safety or study objectives.

Sites / Locations

  • Joseph M. Still Research Foundation

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Invia Motion Endure

Arm Description

Outcomes

Primary Outcome Measures

Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds
Goal of the therapy will be defined by the physician according to initial assessment: Decrease in wound volume Decrease in size of the tunneling area Decrease in size of undermining Decrease in amount of slough Increase in granulation tissue The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft. **Study endpoint will be determined by physician at the time of enrolment, when the goal of therapy is documented**

Secondary Outcome Measures

Evaluation of ease of use and satisfaction
A weekly survey will be obtained from the wound clinic staff members to determine ease of use and satisfaction

Full Information

First Posted
September 7, 2018
Last Updated
March 19, 2020
Sponsor
Medela AG
Collaborators
Joseph M. Still Research Foundation, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT03670225
Brief Title
Evaluating Clinical Acceptance of a NPWT Wound Care System
Official Title
Evaluating Clinical Acceptance of a NPWT Wound Care System to Expected Standards of Care in Post-acute Patients With a Variety of Wound Types
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
October 16, 2018 (Actual)
Primary Completion Date
January 30, 2020 (Actual)
Study Completion Date
January 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Medela AG
Collaborators
Joseph M. Still Research Foundation, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Determine if use of the Medela Invia Motion NPWT system supports acceptable progress towards the goal of therapy when treating patients with a variety of wound types during the evaluation period.
Detailed Description
The primary objective of this study is to determine acceptable progress towards the goal of therapy for a diabetic foot ulcers (DFU) and pressure Injuries/ulcers (PI/PU) wounds when using the Medela Invia Motion Endure NPWT system during 4-week study duration. Goal of therapy will be defined by the physician according to initial assessment: Endpoints (dependent on goal of therapy): Decrease in wound volume Decrease in size of the tunneling area Decrease in size of undermining Decrease in amount of slough Increase in granulation tissue The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft. **Study endpoint will be determined by physician at the time of enrollment, when the goal of therapy is documented** B. Secondary Objectives To evaluate the ease of use from clinicians. To evaluate overall satisfaction from clinicians. C. Tertiary Objectives Adequate management of the exudate

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Foot Ulcer, Pressure Injury, Pressure Ulcer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
non-randomized
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Invia Motion Endure
Arm Type
Other
Intervention Type
Device
Intervention Name(s)
Invia Motion Endure
Intervention Description
NPWT Invia Motion Endure
Primary Outcome Measure Information:
Title
Determine if Invia Motion Endure supports acceptable progress towards the goal of therapy for DFU and PI/PU wounds
Description
Goal of the therapy will be defined by the physician according to initial assessment: Decrease in wound volume Decrease in size of the tunneling area Decrease in size of undermining Decrease in amount of slough Increase in granulation tissue The wound bed is progressing acceptably towards a transition to another treatment modality such as Moist Wound Healing (MWH), surgical closure, or a flap or graft. **Study endpoint will be determined by physician at the time of enrolment, when the goal of therapy is documented**
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Evaluation of ease of use and satisfaction
Description
A weekly survey will be obtained from the wound clinic staff members to determine ease of use and satisfaction
Time Frame
4 weeks
Other Pre-specified Outcome Measures:
Title
Adequate management of the exudate
Description
Measurament of exudate (ml, number of canisters used) will be performed
Time Frame
4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult subjects ≥18 years of age. Signed, informed consent by patient or LAR within 72 hours of admission to burn center. Patient is determined to be in need of NPWT for treatment of a diabetic foot ulcer, pressure injuries/pressure ulcer. Patient is comfortable (e.g. not in pain) Patient is willing and able to adhere to treatment protocol. Exclusion Criteria: Patient not willing to comply with f/u clinic visits. Subjects with Necrotic tissue with eschar present Untreated osteomyelitis Non-enteric and unexplored fistulas Malignancy in wound Exposed vasculature Exposed nerves Exposed anastomotic site of blood vessels or bypasses Exposed organs Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures. Patients with concurrent conditions or co-morbidities that in the opinion of the investigator may compromise patient safety or study objectives.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert F Mullins, MD
Organizational Affiliation
Joseph M. Still Research Foundation
Official's Role
Principal Investigator
Facility Information:
Facility Name
Joseph M. Still Research Foundation
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30909
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
19903300
Citation
Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, Gottrup F, Gurtner GC, Longaker MT. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009 Nov-Dec;17(6):763-71. doi: 10.1111/j.1524-475X.2009.00543.x.
Results Reference
background
Citation
Morrison Informatics, Inc. A comprehensive cost analysis of medicare home oxygen therapy: A study for the American Association for Homecare. June 27, 2006.
Results Reference
background
Citation
C. Marquardt et. al. "Negative pressure wound therapy using PHMB gauze for the management of postoperative subcutaneous surgical site infections" Coloproctology" 36:364-369, 2014
Results Reference
background

Learn more about this trial

Evaluating Clinical Acceptance of a NPWT Wound Care System

We'll reach out to this number within 24 hrs